Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
AzurRx BioPharma Inc Market Cap
Based on ratings from 0 stock analysts, the AzurRx BioPharma Inc stock price is expected to decrease by 100% in 12 months. This is calculated by using the average 12-month stock price forecast for AzurRx BioPharma Inc. The lowest target is $ and the highest is $. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assigned AZRX 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect AzurRx BioPharma Inc to perform worse than the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on AZRX. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of AZRX.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
Data Not Found! | ||||
When did it IPO
2016
Staff Count
0
Country
United States
Sector/Industry
/
CEO
Market Cap
$25.7M
In 2023, AZRX generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that AZRX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 21 Sep 2021
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - The company will start trading on Nasdaq under the new ticker symbol "FBWI" effective September 22.
Why It Matters - The new ticker symbol "FBWI" indicates a potential rebranding or strategic shift, which could impact stock performance and investor sentiment.
Tue, 14 Sep 2021
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - AzurRx BioPharma, Inc. (NASDAQ:AZRX) announced a merger with First Wave Bio, Inc. and will operate under the name First Wave BioPharma. A letter from CEO James Sapirstein was issued to shareholders.
Why It Matters - The merger and rebranding signal a strategic shift for AzurRx, potentially enhancing its market position and attracting investor interest in its GI disease therapies.
Tue, 14 Sep 2021
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - AzurRx BioPharma (AZRX) has acquired First Wave Bio for $229 million and will rebrand itself as First Wave BioPharma post-acquisition.
Why It Matters - The acquisition signals potential growth and diversification for AzurRx, now First Wave BioPharma, impacting its market position and future revenue streams, influencing investor sentiment and stock value.
Wed, 15 Sep 2021
Sentiment - POSITIVE
Source - PennyStocks
Summary - In September 2021, three penny stocks are highlighted as potential buys by top investors, suggesting interest in these lower-priced shares.
Why It Matters - The mention of top investors buying specific penny stocks signals potential growth opportunities, influencing market sentiment and likely increasing trading activity in those stocks.
Mon, 13 Sep 2021
Sentiment - POSITIVE
Source - Benzinga
Summary - AzurRx BioPharma Inc (NASDAQ: AZRX) will acquire First Wave Bio Inc for $229 million in stock and cash, focusing on therapies for autoimmune inflammatory bowel diseases.
Why It Matters - AzurRx's acquisition of First Wave Bio enhances its portfolio in the lucrative IBD market, potentially increasing revenue streams and market competitiveness, which can positively impact stock value.
Mon, 13 Sep 2021
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - AzurRx BioPharma, Inc. (AZRX) CEO James Sapirstein discussed the First Wave Bio acquisition during a conference call, highlighting strategic benefits and future growth plans.
Why It Matters - The acquisition could impact AZRX's market position, future revenue streams, and overall growth strategy, influencing investor sentiment and stock performance.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
